Plasma Tumor Mutation Burden and Response to Pembrolizumab—Letter
Sign Up to like & getrecommendations! Published in 2020 at "Clinical Cancer Research"
DOI: 10.1158/1078-0432.ccr-20-0903
Abstract: Predictive biomarkers are critical for patient selection in immune checkpoint inhibitor (ICI) therapy. However, the term “predictive” are often confused with “prognostic,” leading to inappropriate treatment choice in clinical practice and research. We read with… read more here.
Keywords: burden response; tumor mutation; mutation burden; pembrolizumab letter ... See more keywords